Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
A benzodiazepine (Template:Pron-en, sometimes abbreviated to "benzo") is a psychoactive drug whose core chemical structure is the fusion of a benzene ring and a diazepine ring. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and made available in 1960 by Hoffmann–La Roche, which has also marketed diazepam (Valium) since 1963.
Benzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid, which results in sedative, hypnotic (sleep-inducing), anxiolytic (anti-anxiety), anticonvulsant, muscle relaxant and amnesic action. These properties make benzodiazepines useful in treating anxiety, insomnia, agitation, seizures, muscle spasms, alcohol withdrawal and as a premedication for medical or dental procedures. Benzodiazepines are categorized as either short-, intermediate- or long-acting. Short- and intermediate-acting benzodiazepines are preferred for the treatment of insomnia; longer-acting benzodiazepines are recommended for the treatment of anxiety.
Benzodiazepines are generally safe and effective in the short term, although cognitive impairments and paradoxical effects such as aggression or behavioral disinhibition occasionally occur. Long-term use is controversial due to concerns about adverse psychological and physical effects, increased questioning of effectiveness and because benzodiazepines are prone to cause tolerance, physical dependence and upon cessation of use, a withdrawal syndrome. Withdrawal from benzodiazepines generally leads to improved physical and mental health. The elderly are at an increased risk of suffering from both short- and long-term adverse effects.
There is controversy concerning the safety of benzodiazepines in pregnancy. While they are not major teratogens, uncertainty remains as to whether they cause cleft palate in a small number of babies and whether neurobehavioural effects occur as a result of prenatal exposure; they are known to cause withdrawal symptoms in the newborn. Benzodiazepines can be taken in overdoses and can cause dangerous deep unconsciousness. However, they are much less toxic than their predecessors, the barbiturates, and death rarely results when a benzodiazepine is the only drug taken. When combined with other central nervous system depressants such as alcohol and opiates, the potential for toxicity increases. Benzodiazepines are commonly misused and taken in combination with other drugs of abuse.
The first benzodiazepine, chlordiazepoxide (Librium), was synthesized in 1955 by Leo Sternbach while working at Hoffmann–La Roche on the development of tranquilizers. The pharmacological properties of the compounds prepared initially were disappointing, and Sternbach abandoned the project. Two years later, in April 1957, co-worker Earl Reeder noticed a "nicely crystalline" compound left over from the discontinued project while spring cleaning in the lab. This compound, later named chlordiazepoxide, had not been tested in 1955 because of Sternbach's focus on other issues. Expecting the pharmacology results to be negative and hoping to publish the chemistry-related findings, researchers submitted it for a standard battery of animal tests. Unexpectedly, the compound showed very strong sedative, anticonvulsant and muscle relaxant effects. These impressive clinical findings led to its speedy introduction throughout the world in 1960 under the brand name Librium. Following chlordiazepoxide, diazepam was marketed by Hoffmann–La Roche under the brand name Valium in 1963, and for a while the two were the most commercially successful drugs. The introduction of benzodiazepines led to a decrease in the prescription of barbiturates, and by the 1970s they had largely replaced the older drugs for sedative and hypnotic uses.
The new group of drugs was initially greeted with optimism by the medical profession, but gradually concerns arose; in particular, the risk of dependence became evident in the 1980s. Benzodiazepines have a unique history in that they were responsible for the largest ever class action lawsuit against drug manufacturers in the United Kingdom, involving 14,000 patients and 1,800 law firms that alleged the manufacturers knew of the dependence potential but intentionally withheld this information from doctors. At the same time, 117 general practitioners and 50 health authorities were sued by patients to recover damages for the harmful effects of dependence and withdrawal. This led some doctors to require a signed consent form from their patients and to recommend that all patients be adequately warned of the risks of dependence and withdrawal before starting treatment with benzodiazepines. The court case against the drug manufacturers never reached a verdict; legal aid had been withdrawn and there were allegations that the consultant psychiatrists, the expert witnesses, had a conflict of interest. This litigation led to changes in the British law, making class action law suits more difficult.
Although antidepressants with anxiolytic properties have been introduced, and there is increasing awareness of the adverse effects of benzodiazepines, prescriptions for short term anxiety relief have not significantly dropped. For treatment of insomnia, benzodiazepines are now less popular than nonbenzodiazepines, which include zolpidem, zaleplon and eszopiclone. Nonbenzodiazepines are molecularly distinct, but nonetheless, they work on benzodiazepine receptors.
- See also: List of benzodiazepines
Benzodiazepines possess sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant and amnesic actions, which are useful in a variety of indications such as alcohol dependence, seizures, anxiety, panic, agitation and insomnia. Most are administered orally; however, they can also be given intravenously, intramuscularly or rectally.:189 Benzodiazepines are well-tolerated and are generally safe and effective drugs in the short-term for a wide range of conditions. Tolerance can develop to their effects and there is also a risk of dependence and upon discontinuation a withdrawal syndrome may occur. These factors, combined with other possible secondary effects after prolonged use such as psychomotor, cognitive or memory impairments, limit their long term applicability. The effects of long-term use or misuse include the tendency to cause or worsen cognitive deficits, depression and anxiety.
Due to their effectiveness, tolerability and rapid onset of anxiolytic action, benzodiazepines are frequently used for the treatment of anxiety associated with panic disorder. There is disagreement among expert bodies regarding the long-term use of benzodiazepines for panic disorder. The views range from benzodiazepines being not effective long-term, that they should be reserved for treatment resistant cases or that they are as effective in the long-term as the main alternative agents to selective serotonin reuptake inhibitors.
The American Psychiatric Association (APA) guidelines note that benzodiazepines are generally well tolerated and their use for the short-term treatment for panic disorder is strongly supported by numerous controlled trials. APA states that there is insufficient evidence to recommend any of the established panic disorder treatments over another. The choice of treatment between benzodiazepines, SSRIs, SNRIs, TCAs or psychotherapy should be based on the patient's history, preference and other individual characteristics. Selective serotonin reuptake inhibitors are likely to be the best choice of pharmacotherapy for many patients with panic disorder, but benzodiazepines are also often used, and some studies suggest that these medications are still used with greater frequency than the SSRIs. One advantage of benzodiazepines is that they alleviate the anxiety symptoms much faster than antidepressants, and therefore may be preferred in patients for whom rapid symptom control is critical. However, this advantage is offset by the possibility of developing benzodiazepine dependence. APA does not recommend benzodiazepines for persons with depressive symptoms or a recent history of substance abuse. The APA guidelines state that pharmacotherapy of panic disorder should generally be continued for at least a year, and that clinical experience support continuing benzodiazepine treatment to prevent recurrence. Although major concerns about benzodiazepine tolerance and withdrawal have been raised, there is no evidence for significant dose escalation in patients using benzodiazepines long-term. For many such patients stable doses of benzodiazepines retain their efficacy over several years.
Guidelines issued by the UK-based National Institute for Health and Clinical Excellence (NICE) do not recommend use of benzodiazepines beyond two to four weeks, as tolerance and physical dependence develop rapidly, with withdrawal symptoms including rebound anxiety occurring after six weeks or more of use. Nevertheless, benzodiazepines continue to be prescribed for the long-term treatment of anxiety disorders, although specific antidepressants and psychological therapies are recommended as the first line treatment options with the anticonvulsant drug pregabalin indicated as a second or third line treatment suitable for long term use. NICE stated that long-term use of benzodiazepines for panic disorder with or without agoraphobia is an unlicensed indication, does not have long term efficacy, and is therefore not recommended by clinical guidelines. Psychological therapies such as cognitive behavioural therapy are recommended as a first line therapy for panic disorder; benzodiazepine use has been found to interfere with therapeutic gains from these therapies.
Generalized anxiety disorderEdit
Benzodiazepines have robust efficacy in the short-term management of generalized anxiety disorder (GAD), but were not shown to be effective in producing long-term improvement overall. According to National Institute for Health and Clinical Excellence (NICE), benzodiazepines can be used in the immediate management of GAD, if necessary. However, they should not usually be given for longer than 2-4 weeks. The only medications NICE recommends for the longer term management of GAD are antidepressants.
Similarly, Canadian Psychiatric Association (CPA) recommends benzodiazepines alprazolam, bromazepam, lorazepam, and diazepam only as a second-line choice, if the treatment with two different antidepressants was unsuccessful. Although they are second-line agents, benzodiazepines can be used for a limited time to relieve severe anxiety and agitation. CPA guidelines note that after 4-6 weeks the effect of benzodiazepines may decrease to the level of placebo, and that benzodiazepines are less effective than antidepressants in alleviating ruminative worry, the core symptom of GAD. However, in some cases a prolonged treatment with benzodiazepines as the add-on to an antidepressant may be justified.
Benzodiazepines can be useful for short-term treatment of insomnia. They improve sleep related problems by shortening the time spent in bed before falling asleep, prolonging the sleep time and generally reducing wakefulness. Their use beyond two to four weeks is not recommended due to the risk of dependence. Preferably, benzodiazepines are taken intermittently and at the lowest effective dose. However, they worsen sleep quality by increasing light sleep and decreasing deep sleep. Other drawbacks of hypnotics, including benzodiazepines, are possible tolerance to their effects, rebound insomnia and reduced slow wave sleep and a withdrawal period typified by rebound insomnia and a prolonged period of anxiety and agitation. Among the benzodiazepines approved in the US for the treatment of insomnia, the fast acting ones with short half-lives such as estazolam, triazolam, and temazepam are recommended. Longer-acting benzodiazepines such as nitrazepam and diazepam have residual effects that may persist into the next day and are generally not recommended.
It is not clear whether the new nonbenzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar. According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines. This may make the non-benzodiazepines preferable as the first-line long-term treatment of insomnia. However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and patient's preference.
It has been argued that long term use of hypnotics and over prescribing of these drugs represents an unjustifiable risk, especially to the elderly, and is harmful for the public health in general.
Prolonged convulsive epileptic seizures are a medical emergency that can usually be dealt with effectively by administering fast-acting benzodiazepines, which are potent anticonvulsants. In a hospital environment, intravenous lorazepam and diazepam are first-line choices, with a preference for diazepam due to its longer duration of action. In the community, intravenous administration is not practical and so rectal diazepam or (more recently) buccal midazolam are used, with a preference for midazolam as its administration is easier and more socially acceptable.
When benzodiazepines were first introduced, they were enthusiastically adopted for treating all forms of epilepsy. However, drowsiness and tolerance become problems with continued use and none are now considered first-line choices for long-term epilepsy therapy. Clobazam is widely used by specialist epilepsy clinics worldwide (but it is not available in the US) and clonazepam is popular in France. In the UK, both clobazam and clonazepam are second-line choices for treating many forms of epilepsy. Clobazam also has a useful role for very short-term seizure prophylaxis and in catamenial epilepsy. Discontinuation after long term use in epilepsy requires additional caution because of the risks of rebound seizures. Therefore, the dose is slowly tapered over a period of up to six months or longer.
Chlordiazepoxide is the most commonly used benzodiazepine for alcohol detoxification, but diazepam may be used as an alternative. Both are used in the detoxification of individuals who are motivated to stop drinking, and are prescribed for a short period of time to reduce to the risks of tolerance and dependence to the benzodiazepine medication itself.:275 The benzodiazepines with a longer half life make detoxification more tolerable, and dangerous alcohol withdrawal effects are less likely to occur. On the other hand, short-acting benzodiazepines may lead to breakthrough seizures, and are therefore not recommended for detoxification in an outpatient setting. Oxazepam and lorazepam are often used in patients at risk of drug accumulation, particularly the elderly and those with cirrhosis, because they are metabolized differently from other benzodiazepines, through conjugation.
Benzodiazepines are the preferred choice in the management of alcohol withdrawal syndrome, particularly for the prevention and treatment of the dangerous complication of seizures and in subduing severe delirium. Lorazepam is the only benzodiazepine with predictable intramuscular absorption and it is the most effective in preventing and controlling acute seizures.
Benzodiazepines are sometimes used in the treatment of acute anxiety as they bring about rapid and marked or moderate relief of symptoms in most individuals; however, they are not recommended beyond 2-4 weeks of use due to risks of tolerance and dependence and a lack of long-term effectiveness. Compared to other pharmacological treatments benzodiazepines are twice as likely to lead to a relapse of the underlying condition upon discontinuation. Psychological therapies and other pharmacological therapies are recommended for the long-term treatment of generalised anxiety disorder. Antidepressants have higher remission rates and are generally safe and effective in the short and long-term.
Benzodiazepines are often prescribed for a wide range of conditions. Some of the most notable indications are summarised below.
- They can be very useful in intensive care to sedate patients receiving mechanical ventilation, or those in extreme distress. Caution is exercised in this situation due to the occasional occurrence of respiratory depression; it is recommended that benzodiazepine overdose treatment facilities should be available.
- Benzodiazepines are effective as premedication given a couple of hours before surgery to relieve anxiety. They also produce amnesia, which can be useful as patients will not be able to remember any unpleasantness from the procedure. They are also used in patients with dental phobia as well as some ophthalmic procedures like refractive surgery; although such use is controversial and only recommended for those who are very anxious. Midazolam is the most commonly prescribed for this use because of its strong sedative actions and fast recovery time, as well as its water solubility which reduces pain upon injection. Diazepam and lorazepam are sometimes used; lorazepam has particularly marked amnesic properties that may make it more effective when amesia is the desired effect.:693
- Benzodiazepines are well known for their strong muscle-relaxing properties and can be useful in the treatment of muscle spasms,:577–578 although tolerance often develops to their muscle relaxant effects. Baclofen is sometimes used as an alternative to benzodiazepines.
- Benzodiazepines are also used to treat the acute panic caused by hallucinogen intoxication. Benzodiazepines are also used to calm the acutely agitated individual and can, if required, be given via an intramuscular injection. They can sometimes be effective in the short-term treatment of psychiatric emergencies such as acute psychosis as in schizophrenia or mania, bringing about rapid tranquillization and sedation until the effects of lithium or neuroleptics (antipsychotics) take effect. Lorazepam is most commonly used but clonazepam is sometimes prescribed for acute psychosis or mania; their long-term use is not recommended due to risks of dependence.:204
The most common side effects of benzodiazepines are related to their sedating and muscle-relaxing action. They include drowsiness, dizziness and decreased alertness and concentration. Lack of coordination may result in ataxia, falls and injuries, particularly in the elderly. Another result is impairment of driving skills and increased risk of road traffic accidents. Decreased libido and erection problems are a common side effect. Depression and disinhibition may emerge. Hypotension and suppressed breathing may be encountered with intravenous use. Less common side effects include nausea and changes in appetite, blurred vision, confusion, euphoria, depersonalization and nightmares. Cases of liver toxicity have been described but are very rare.:183–189
Paradoxical reactions, such as aggression, violence, impulsivity, irritability and suicidal behavior sometimes occur. These reactions have been explained as consequences of disinhibition, that is loss of control over socially unacceptable behavior. Paradoxical reactions are rare in the general population, with an incidence rate below 1% and similar to placebo. However, they occur with greater frequency in recreational abusers, individuals with borderline personality disorder, children and patients on high-dosage regimes. In these groups, impulse control problems are perhaps the most important risk factor for disinhibition; learning disabilities and neurological disorders are also significant risks. Most reports of disinhibition involve high doses of high-potency benzodiazepines. Paradoxical effects may also appear after chronic use of benzodiazepines.
The short-term use of benzodiazepines adversely affects multiple areas of cognition; most notably, it interferes with the formation and consolidation of memories of new material and may induce complete anterograde amnesia. However, researchers hold contrary opinions regarding the effects of long-term administration. One view is that many of the short-term effects continue into the long-term and may even worsen, and are not resolved after quitting benzodiazepines. Another view maintains that cognitive deficits in chronic benzodiazepine users occur only for a short period after the dose, or that the anxiety disorders is the cause of these deficits. While the definitive studies are lacking, the former view recently received support from a meta-analysis of 13 small studies. This meta-analysis found that long-term use of benzodiazepines was associated with moderate to large adverse effects on all areas of cognition, with visuospatial memory being the most commonly detected impairment. Some of the other impairments reported were decreased IQ, visiomotor coordination, information processing, verbal learning and concentration. The authors of the meta-analysis and a later reviewer noted that the applicability of this meta-analysis is limited because the subjects were taken mostly from withdrawal clinics, the coexisting drug, alcohol use and psychiatric disorders were not defined, and several of the included studies conducted the cognitive measurements during the withdrawal period.
The long-term adverse effects of benzodiazepines include a general deterioration in physical and mental health and tend to increase with time. Not everyone however, experiences problems with long-term use. The adverse effects can include cognitive impairments and affective and behavioural problems. Feelings of turmoil, difficulty in thinking constructively, loss of sex-drive, agoraphobia and social phobia, increasing anxiety and depression, loss of interest in leisure pursuits and interests, an inability to experience or express feelings also occurs. Additionally an altered perception of self, environment and relationships may occur.
- Main article: Benzodiazepine dependence
Tolerance, dependence and withdrawalEdit
The main problem of the chronic use of benzodiazepines is the development of tolerance and dependence. Tolerance manifests itself as diminished pharmacological effect and develops relatively quickly to the sedative, hypnotic, anticonvulsant and muscle relaxant actions of benzodiazepines. Tolerance to anti-anxiety effects develops more slowly with little evidence of continued effectiveness beyond four to six months of continued use. Tolerance to the amnesic effects, generally, does not occur. However, controversy exists as to tolerance to the anxiolytic effects with some evidence that benzodiazepines retain efficacy and opposing evidence from a systematic review of the literature that tolerance frequently occurs and some evidence that anxiety may worsen with long-term use. The question of tolerance to the amnesic effects of benzodiazepines is similarly unclear. Some evidence suggests that partial tolerance does develop, and "the memory impairment is limited to a narrow window within 90 minutes after each dose".
Discontinuation of benzodiazepines or abrupt reduction of the dose, even after a relatively short course of treatment (three to four weeks), may result in two groups of symptoms—rebound and withdrawal. Rebound symptoms are the return of the symptoms for which the patient was treated but worse than before. Withdrawal symptoms are the new symptoms that occur when the benzodiazepine is stopped. They are the main sign of physical dependence.
Withdrawal symptoms and managementEdit
The most frequent symptoms of withdrawal from benzodiazepines are insomnia, gastric problems, tremors, agitation, fearfulness and muscle spasms. The less frequent effects are irritability, sweating, depersonalization, derealization, hypersensitivity to stimuli, depression, suicidal behavior, psychosis, seizures and delirium tremens. Severe symptoms usually occur as a result of abrupt or over-rapid withdrawal. Abrupt withdrawal can be dangerous, therefore a gradual reduction regime is recommended.
Symptoms may also occur during a gradual dosage reduction, but are typically less severe and may persist as part of a protracted withdrawal syndrome for months after cessation of benzodiazepines. Approximately 10% of patients will experience a notable protracted withdrawal syndrome which can persist for many months or in some cases a year or longer. Protracted symptoms tend to resemble those seen during the first couple of months of withdrawal but usually are of a sub acute level of severity. Such symptoms do gradually lessen over time, eventually disappearing altogether.
Benzodiazepines have a reputation with patients and doctors for causing a severe and traumatic withdrawal; however, this is in large part due to the withdrawal process being poorly managed. Over-rapid withdrawal from benzodiazepines increases the severity of the withdrawal syndrome and increases the failure rate. A slow and gradual withdrawal customised to the individual and, if indicated, psychological support is the most effective way of managing the withdrawal. Opinion as to the time needed to complete withdrawal ranges from four weeks to several years. A goal of less than six months has been suggested, but due to factors such as dosage and type of benzodiazepine, reasons for prescription, lifestyle, personality, environmental stresses and amount of available support, a year or more may be needed to withdraw.:183–184 Withdrawal is best managed by transferring the physically-dependent patient to an equivalent dose of diazepam because it has the longest half-life of all of the benzodiazepines, is metabolised into long acting active metabolites and is available in low-potency tablets, which can be quartered for smaller doses. A further benefit is that it is available in liquid form which allows for even smaller reductions. Chlordiazepoxide which also has a long half life and long acting active metabolites can be used as an alternative. Nonbenzodiazepines are contraindicated during benzodiazepine withdrawal as they are cross tolerant with benzodiazepines and can induce dependence. Alcohol is also cross tolerant with benzodiazepines and more toxic and thus caution is needed to avoid replacing one dependence with another. During withdrawal, fluoroquinolone-based antibiotics are best avoided if possible; they displace benzodiazepines from their binding site and reduce GABA function and thus may aggravate withdrawal symptoms. Antipsychotics are not recommended for benzodiazepine withdrawal (or other CNS depressant withdrawal states) especially clozapine, olanzapine or low potency phenothiazines eg chlorpromazine as they lower the seizure threshold and can worsen withdrawal effects; if used extreme caution is required.
Withdrawal from long term benzodiazepines is beneficial for most individuals. Withdrawal of benzodiazepines from long term users generally leads to improved physical and mental health particularly in the elderly; although some long term users report continued benefit from taking benzodiazepines, this may be the result of suppression of withdrawal effects.
Because of their muscle relaxant action, benzodiazepines may cause respiratory depression in susceptible individuals. For that reason, they are contraindicated in people with myasthenia gravis, sleep apnea, bronchitis and COPD. Caution is required when benzodiazepines are used in people with personality disorders or mental retardation because of frequent paradoxical reactions. In major depression, they may precipitate suicidal tendencies and are sometimes used for suicidal overdoses. Individuals with a history of alcohol, opioid and barbiturate abuse should generally avoid benzodiazepines as there is a risk of life-threatening interactions with these drugs.
Exposure to benzodiazepines during pregnancy has been associated with a slightly increased (from 0.06 to 0.07%) risk of cleft palate in newborns, a controversial conclusion as some studies find no association between benzodiazepines and cleft palate. Their use by expectant mothers shortly before the delivery may result in a floppy infant syndrome, with the newborns suffering from hypotonia, hypothermia, lethargy and breathing and feeding difficulties. Cases of neonatal withdrawal syndrome have been described in infants chronically exposed to benzodiazepines in utero. This syndrome may be hard to recognize as it starts several days after delivery, for example, as late as 21 day for chlordiazepoxide. The symptoms include tremors, hypertonia, hyperreflexia, hyperactivity and vomiting and may last for up to three to six months. Tapering down the dose during pregnancy may lessen its severity. If used in pregnancy, those benzodiazepines with a better and longer safety record, such as diazepam or chlordiazepoxide, are recommended over potentially more harmful benzodiazepines, such as alprazolam or triazolam. Using the lowest effective dose for the shortest period of time minimizes the risks to the unborn child.
The benefits of benzodiazepines are least and the risks are greatest in the elderly. The elderly are at an increased risk of dependence and are more sensitive to the adverse effects such as memory problems, daytime sedation, impaired motor coordination and increased risk of motor vehicle accidents and falls. The long-term effects of benzodiazepines and benzodiazepine dependence in the elderly can resemble dementia, depression or anxiety syndromes and progressively worsens over time. Adverse effects on cognition can be mistaken for the effects of old age. The benefits of withdrawal include improved cognition, alertness, mobility, reduced risk incontinance and a reduced risk of falls and fractures. The success of gradual-tapering benzodiazepines is as great in the elderly as in younger people. Benzodiazepines should be prescribed to the elderly only with caution and only for a short period at low doses. Short to intermediate-acting benzodiazepines are preferred in the elderly such as oxazepam and temazepam. The high potency benzodiazepines alprazolam and triazolam and long-acting benzodiazepines are not recommended in the elderly due to increased adverse effects. Nonbenzodiazepines such as zaleplon and zolpidem and low doses of sedating antidepressants are sometimes used as alternatives to benzodiazepines.
Long-term use of benzodiazepines has been associated with increased risk of cognitive impairment, but its relationship with dementia remains inconclusive. The association of a past history of benzodiazepine use and cognitive decline is unclear, with some studies reporting a lower risk of cognitive decline in former users, some finding no association and some indicating an increased risk of cognitive decline.
Benzodiazepines are sometimes prescribed to treat behavioral symptoms of dementia. However, similarly to antidepressants they have little evidence of effectiveness, although antipsychotics have shown some benefit. Cognitive impairing effects of benzodiazepines which occur frequently in the elderly can also worsen dementia.
Benzodiazepines share a similar chemical structure and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the conductance of this inhibitory channel; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Other less important mechanisms of action are also known.
The term benzodiazepine is the chemical name for the heterocyclic ring system (see figure to the right) which is a fusion between the benzene and diazepine ring systems. Under Hantzsch–Widman nomenclature, a diazepine is a heterocycle with two nitrogen atoms, five carbon atom and the maximum possible number of cumulative double bonds. The "benzo" prefix indicates the benzene ring fused onto the diazepine ring.
Benzodiazepine drugs are substituted 1,4-benzodiazepines, although the chemical term can refer to many other compounds which do not have useful pharmacological properties. Different benzodiazepine drugs have different side groups attached to this central structure. The different side groups affect the binding of the molecule to the GABAA receptor and so modulate the pharmacological properties. Many of the pharmacologically active "classical" benzodiazepine drugs contain the 5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one substructure (see figure to the right).
Nonbenzodiazepines also bind to the benzodiazepine binding site on the GABAA receptor and possess similar pharmacological properties. While the nonbenzodiazepines are by definition structurally unrelated to the benzodiazepines, both classes of drugs share a common pharmacophore (see figure to the lower right) which explains their binding to a common receptor site.
Mechanism of actionEdit
Benzodiazepines work by increasing the efficiency of a natural brain chemical, GABA, to decrease the excitability of certain types of brain cells called neurons. This reduces the communication between neurons and therefore has a calming effect on many of the functions of the brain.
GABA controls the excitability of neurons by binding to the GABAA receptor. The GABAA receptor is a protein complex located in the synapses of neurons. All GABAA receptors contain an ion channel that conducts chloride ions across neuronal cell membranes and two binding sites for the neurotransmitter gamma-aminobutyric acid (GABA), while a subset of GABAA receptor complexes also contain a single binding site for benzodiazepines. Binding of benzodiazepines to this receptor complex promotes binding of GABA, which in turn increases the conduction of chloride ions across the neuronal cell membrane. This increased conductance raises the membrane potential of the neuron resulting in inhibition of neuronal firing. In addition, different GABAA receptor subtypes have varying distributions within different regions of the brain and therefore control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions. In terms of the mechanism of action of benzodiazepines, their similarities are too great to separate them into individual categories such as anxiolytic or hypnotic. For example, a hypnotic administered in low doses will produce anxiety relieving effects, whereas a benzodiazepine marketed as an anti-anxiety drug will at higher doses induce sleep.
The subset of GABAA receptors that also bind benzodiazepines are referred to as benzodiazepine receptors (BzR). The GABAA receptor is a heteromer composed of five subunits, most commonly two α's, two β's and one γ (α2β2γ). For each subunit, many subtypes exist (α1-6, β1-3 and γ1-3). GABAA receptors that are made up of different combinations of subunit subtypes have different properties, different distributions in the brain and different activities relative to pharmacological and clinical effects. Benzodiazepines bind at the interface of the α and γ subunits on the GABAA receptor. Binding also requires that alpha subunits contain a histidine amino acid residue, (i.e., α1, α2, α3 and α5 containing GABAA receptors). For this reason, benzodiazepines show no affinity for GABAA receptors containing α4 and α6 subunits with an arginine instead of a histidine residue.
Once bound to the benzodiazepine receptor, the benzodiazepine ligand locks the benzodiazepine receptor into a conformation in which it has a greater affinity for the GABA neurotransmitter. This increases the frequency of the opening of the associated chloride ion channel and hyperpolarizes the membrane of the associated neuron. The inhibitory effect of the available GABA is potentiated, leading to sedatory and anxiolytic effects. Furthermore, different benzodiazepines can have different affinities for BzRs made up of different collection of subunits. For instance, those with high activity at the α1 are associated with stronger hypnotic effects, whereas those with higher affinity for GABAA receptors containing α2 and/or α3 subunits have good anti-anxiety activity.
The benzodiazepine class of drugs also interact with peripheral benzodiazepine receptors. Peripheral benzodiazepine receptors are present in peripheral nervous system tissues, glial cells and to a lesser extent the central nervous system. These peripheral receptors are not structurally related nor coupled to GABAA receptors. They modulate the immune system and are involved in the body response to injury. Benzodiazepines also function as weak adenosine reuptake inhibitors. It has been suggested that some of their anticonvulsant, anxiolytic and muscle relaxant effects may be in part mediated by this action.
A benzodiazepine can be placed into one of three groups by its elimination half-life, or time it takes for the body to eliminate half of the dose. Some benzodiazepines have long acting active metabolites such as diazepam and chlordiazepoxide which are metabolised into desmethyldiazepam. Desmethyldiazepam has a half life of 36-200 hours.
- Short-acting compounds have a half-life of 1–8 hours. They have few residual effects if taken before bedtime, rebound insomnia may occur upon discontinuation and they might cause day time withdrawal symptoms such as next day rebound anxiety with prolonged usage. Examples are brotizolam, midazolam and triazolam.
- Intermediate-acting compounds have a half-life of 8–40 hours. They may have some residual effects in the first half of the day if used as a hypnotic. Rebound insomnia, however, is more common upon discontinuation of intermediate-acting benzodiazepines than longer acting benzodiazepines. Examples are estazolam, flunitrazepam, lormetazepam, nitrazepam and temazepam.
- Long-acting compounds have a half-life of 40–200 hours. They have a risk of accumulation in the elderly and in individuals with severely impaired liver function, but they have a reduced severity of rebound effects and withdrawal. Examples are diazepam and chlordiazepoxide.
Individual benzodiazepines may have different interactions with certain drugs. Depending on their metabolism pathway, benzodiazepines can be roughly divided into two groups. The largest group consists of those that are metabolized by cytochrome P450 (CYP450) enzymes and possess significant potential for interactions with other drugs. The other group comprises those that are metabolized through glucuronidation, such as lorazepam, oxazepam and temazepam and generally have few drug interactions.
Many drugs, including oral contraceptives, some antibiotics, antidepressants and antifungal agents, inhibit cytochrome enzymes in the liver. They reduce the rate of elimination of the benzodiazepines that are metabolized by CYP450, leading to possibly excessive drug accumulation and increased side effects. Conversely, drugs that induce cytochrome P450 enzymes, such as St John's wort, the antibiotic rifampicin and the anticonvulsants carbamazepine and phenytoin, accelerate elimination of many benzodiazepines and decrease their action. Taking benzodiazepines with alcohol, opioids and other central nervous system depressants potentiates their action. This often results in increased sedation, impaired motor coordination, suppressed breathing and other adverse effects that may potentially be lethal. Antacids may slow down absorption of some benzodiazepines; however, this effect is marginal and inconsistent.
- Main article: Benzodiazepine overdose
Although benzodiazepines are much safer in overdose than their predecessors, the barbiturates, they can still cause problems in overdose. Taken alone, they rarely cause severe complications in overdose; statistics in England showed that benzodiazepines were responsible for 3.8% of all deaths by poisoning from a single drug. However, combining these drugs with alcohol, opiates or tricyclic antidepressants markedly raises the toxicity. The elderly are more sensitive to the side effects of benzodiazepines, and poisoning may even occur from their long-term use. The various benzodiazepines differ in their toxicity; alprazolam appears to be most toxic in overdose and when used with other drugs. The symptoms of a benzodiazepine overdose may include; drowsiness, slurred speech, nystagmus, hypotension, ataxia, coma, respiratory depression and cardiorespiratory arrest.
A reversal agent for benzodiazepines exists, flumazenil (Anexate). Its use as an antidote in an overdose however is controversial. Numerous contraindications to its use exist. It is contraindicated in patients with a history of long term use of benzodiazepines, those who have ingested a substance that lowers the seizure threshold or may cause an arrhythmia, and in those with abnormal vital signs. One study found that only 10% of the patient population presenting with a benzodiazepine overdose are suitable candidates for treatment with flumazenil.
- Main article: Benzodiazepine drug misuse
Benzodiazepines are considered major drugs of abuse. Internationally, benzodiazepines are categorized as Schedule IV controlled drugs, apart from flunitrazepam which is a Schedule III drug under the Convention on Psychotropic Substances. Some variation in drug scheduling exists in individual countries; for example in the United Kingdom midazolam and temazepam are Schedule III controlled drugs. Benzodiazepine abuse ranges from occasional binges on large doses, to chronic and compulsive drug abuse of high doses. Benzodiazepine abuse is mostly limited to individuals who abuse other drugs, i.e. poly-drug abusers. The majority of prescribed users do not abuse their medication.
Benzodiazepines are used recreationally and by problematic drug misusers. Mortality is higher among poly-drug misusers that also use benzodiazepines. Heavy alcohol use also increases mortality among poly-drug users. Dependence and tolerance, often coupled with dosage escalation, to benzodiazepines can develop rapidly among drug misusers; withdrawal syndrome may appear after as little as three weeks of continuous use. Long-term use has the potential to cause both physical and psychological dependence and severe withdrawal symptoms such as depression, anxiety and panic attacks, and agoraphobia. Benzodiazepines and in particular temazepam, are sometimes used intravenously, which if done incorrectly or in an unsterile manner, can lead to medical complications including abscesses, cellulitis, thrombophlebitis, arterial puncture, deep vein thrombosis and gangrene. Sharing syringes and needles for this purpose also brings up the possibility of transmission of hepatitis, AIDS and other diseases. Benzodiazepines are also misused intranasally which may have additional health consequences. Once benzodiazepine dependence has been established, a clinician usually converts the patient to an equivalent dose of diazepam before beginning a gradual reduction program.
A 1999–2005 Australian police survey of detainees reported preliminary findings that self-reported users of benzodiazepines were less likely than non-user detainees to work full-time and more likely to receive government benefits, use methamphetamine or heroin and be arrested or imprisoned. Benzodiazepines are sometimes used for criminal purposes; they serve to incapacitate a victim in cases of drug assisted rape or robbery.
See also Edit
- Anticonvulsive drugs
- Benzodiazepine agonists
- Benzodiazepine antagonists
- Hypnotic drugs
- Muscle relaxing drugs
- Tranquillizing drugs
- ↑ 1.0 1.1 Shorter E (2005). "Benzodiazepines" A Historical Dictionary of Psychiatry, 41–2, Oxford University Press.
- ↑ 2.0 2.1 Page C, Michael C, Sutter M, Walker M, Hoffman BB (2002). Integrated Pharmacology, 2nd, C.V. Mosby.
- ↑ 3.0 3.1 Olkkola KT, Ahonen J (2008). Midazolam and other benzodiazepines. Handb Exp Pharmacol 182 (182): 335–60.
- ↑ 4.0 4.1 Dikeos DG, Theleritis CG, Soldatos CR (2008). "Benzodiazepines: effects on sleep" Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ (eds.) Sleep Disorders: Diagnosis and Therapeutics, 220–2, Informa Healthcare.
- ↑ 5.0 5.1 Saïas T, Gallarda T (2008). [Paradoxical aggressive reactions to benzodiazepine use: a review]. Encephale 34 (4): 330–6.
- ↑ 6.0 6.1 Lader M (2008). Effectiveness of benzodiazepines: do they work or not?. Expert Rev Neurother 8 (8): 1189–91.
- ↑ 7.0 7.1 7.2 7.3 Lader M, Tylee A, Donoghue J (2009). Withdrawing benzodiazepines in primary care. CNS Drugs 23 (1): 19–34.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 Ashton H (2005). The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18 (3): 249–55.
- ↑ 9.0 9.1 9.2 Ashton H (2004). "Benzodiazepine dependence" Haddad P, Dursun S, Deakin B (eds.) Adverse Syndromes and Psychiatric Drugs: A Clinical Guide, 239–60, Oxford University Press.
- ↑ 10.0 10.1 10.2 McIntosh A, Semple D, Smyth R, Burns J, Darjee R (2005). "Depressants" Oxford Handbook of Psychiatry, 1st, Oxford University Press.
- ↑ 11.0 11.1 11.2 American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Obstetrics (2008). ACOG Practice Bulletin no. 92: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111 (4): 1001–20.
- ↑ 12.0 12.1 Fraser AD (1998). Use and abuse of the benzodiazepines. Ther Drug Monit 20 (5): 481–9.
- ↑ 13.0 13.1 13.2 Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M (2009). A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 18 (2): 93–103.
- ↑ 14.0 14.1 White JM, Irvine RJ (1999). Mechanisms of fatal opioid overdose. Addiction 94 (7): 961–72.
- ↑ 15.0 15.1 Lader MH (1999). Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. Eur Neuropsychopharmacol 9 (Suppl 6): S399–405.
- ↑ Sternbach LH (1979). The benzodiazepine story. J Med Chem 22 (1): 1–7.
- ↑ Miller NS, Gold MS (1990). Benzodiazepines: reconsidered. Adv Alcohol Subst Abuse 8 (3–4): 67–84.
- ↑ King MB (1992). Is there still a role for benzodiazepines in general practice?. Br J Gen Pract 42 (358): 202–5.
- ↑ Peart R. Memorandum by Dr Reg Peart. Minutes of Evidence. Select Committee on Health, House of Commons, UK Parliament. URL accessed on 2009-05-27.
- ↑ (Jul-Aug 2007). [New hypnotics: perspectives from sleep physiology]. Vertex 18 (74): 294–9.
- ↑ Lemmer B (2007). The sleep–wake cycle and sleeping pills. Physiol Behav 90 (2–3): 285–93.
- ↑ 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 Royal Pharmaceutical Society of Great Britain (2009). British National Formulary (BNF 57), BMJ Group and RPS Publishing.
- ↑ 23.0 23.1 Perugi G, Frare F, Toni C (2007). Diagnosis and treatment of agoraphobia with panic disorder. CNS Drugs 21 (9): 741–64.
- ↑ Tesar GE (1990). High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. J Clin Psychiatry 51 (Suppl): 4–10; discussion 50–3.
- ↑ Faught E (2004). Treatment of refractory primary generalized epilepsy. Rev Neurol Dis 1 (Suppl 1): S34–43.
- ↑ Allgulander C, Bandelow B, Hollander E (2003). WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8 (Suppl 1): 53–61.
- ↑ Stevens JC, Pollack MH (2005). Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. Journal of Clinical Psychiatry 66 (Suppl 2): 21–27.
- ↑ 28.0 28.1 28.2 28.3 28.4 28.5 McIntosh A, Cohen A, Turnbull N et al. (2004). Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. (PDF) National Collaborating Centre for Primary Care. URL accessed on 2009-06-16.
- ↑ Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (October 2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 3 (4): 171–99.
- ↑ 30.0 30.1 30.2 Work Group on Panic Disorder. APA Practice Guideline for the Treatment of Patients With Panic Disorder, Second Edition. (PDF) URL accessed on 07/12/09.
- ↑ Barbui C, Cipriani A (2009). Proposal for the inclusion in the WHO Model List of Essential Medicines of a selective serotonin-reuptake inhibitor for Generalised Anxiety Disorder. (PDF) WHO Collaborating Centre for Research and Training in Mental Health. URL accessed on 2009-06-23.
- ↑ Cloos JM, Ferreira V (2009). Current use of benzodiazepines in anxiety disorders. Current Opinion in Psychiatry 22 (1): 90–95.
- ↑ Martin JL, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C (September 2007). Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J. Psychopharmacol. (Oxford) 21 (7): 774–82.
- ↑ (2007). Clinical Guideline 22 (amended). Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. (PDF) National Institute for Health and Clinical Excellence. URL accessed on 2009-08-08.
- ↑ Canadian Psychiatric Association (July 2006). Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 51 (8 Suppl 2): 51S–55S.
- ↑ 36.0 36.1 36.2 36.3 (2004). Technology Appraisal Guidance 77. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. (PDF) National Institute for Clinical Excellence. URL accessed on 2009-07-26.
- ↑ 37.0 37.1 37.2 Ramakrishnan K, Scheid DC (August 2007). Treatment options for insomnia. Am Fam Physician 76 (4): 517–26.
- ↑ (13 Decemember 2009) Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research, 128-130, Springer Publishing Company.
- ↑ 39.0 39.1 39.2 Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M (2005). Manifestations and Management of Chronic Insomnia in Adults. Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment Number 125. (PDF)
- ↑ (2004). What's wrong with prescribing hypnotics?. Drug Ther Bull 42 (12): 89–93. NeLM summary.
- ↑ Scottish Intercollegiate Guidelines Network (2005). Diagnosis and management of epilepsy in adults. (PDF) URL accessed on 2009-06-05.
- ↑ 42.0 42.1 Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R (2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care. (PDF) Royal College of General Practitioners. URL accessed on 2009-06-02.
- ↑ 43.0 43.1 43.2 Shorvon SD (2009). Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959–2009. Epilepsia 50 (Suppl 3): 93–130.
- ↑ Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R (2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care (Appendix B). (PDF) Royal College of General Practitioners. URL accessed on 2009-06-02.
- ↑ Ashworth M, Gerada C (1997). ABC of mental health. Addiction and dependence--II: Alcohol. BMJ 315 (7104): 358–60.
- ↑ Kraemer KL, Conigliaro J, Saitz R (1999). Managing alcohol withdrawal in the elderly. Drugs Aging 14 (6): 409–25.
- ↑ Prater CD, Miller KE, Zylstra RG (1999). Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician 60 (4): 1175–83.
- ↑ Ebell MH (2006). Benzodiazepines for alcohol withdrawal. Am Fam Physician 73 (7): 1191.
- ↑ Peppers MP (1996). Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 16 (1): 49–57.
- ↑ (Jul 2009). Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids.. Crit Care Clin 25 (3): 431–49, vii.
- ↑ (Feb 2008). [The preoperative medication: background and specific indications for the selection of the drugs]. Anasthesiol Intensivmed Notfallmed Schmerzther 43 (2): 134–43.
- ↑ (May 2007). Enteral sedation: safety, efficacy, and controversy.. Compend Contin Educ Dent 28 (5): 264–71; quiz 272, 282.
- ↑ Mañon-Espaillat R, Mandel S (1999). Diagnostic algorithms for neuromuscular diseases. Clin Podiatr Med Surg 16 (1): 67–79.
- ↑ Wyatt JP, Illingworth RN, Robertson CE, Clancy MJ, Munro PT (2005). "Poisoning" Oxford Handbook of Accident and Emergency Medicine, 2nd, 173–208, Oxford University Press.
- ↑ Zimbroff DL (2008). Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs 22 (3): 199–212.
- ↑ Curtin F, Schulz P (2004). Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 78 (3): 201–8.
- ↑ Gillies D, Beck A, McCloud A, Rathbone J, Gillies D (2005). Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev (4): CD003079.
- ↑ 58.0 58.1 58.2 58.3 58.4 Ballenger JC (2000). "Benzodiazepine receptors agonists and antagonists" Sadock VA, Sadock BJ, Kaplan HI (eds.) Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 7th, 2317–23, Lippincott Williams & Wilkins.
- ↑ 59.0 59.1 Tasman A, Lieberman JA (2006). Handbook of Psychiatric Drugs, Wiley.
- ↑ Rapoport MJ, Lanctôt KL, Streiner DL (2009). Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry 70 (5): 663–73.
- ↑ Orriols L, Salmi LR, Philip P (2009). The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf 18 (8): 647–58.
- ↑ (2005). Benzodiazepines – oral. MedicineNet. URL accessed on 2008-04-10.
- ↑ 63.0 63.1 Paton C (2002). Benzodiazepines and disinhibition: a review. Psychiatr Bull R Coll Psychiatr 26 (12): 460–2.
- ↑ Bond AJ (1998). Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications. CNS Drugs 9 (1): 41–57.
- ↑ Drummer OH (2002). Benzodiazepines—effects on human performance and behavior. Forensic Sci Rev 14 (1–2): 1–14.
- ↑ 66.0 66.1 Ashton H (2007). "Drug dependency: benzodiazepines" Ayers S, Baum A, McManus C, Newman S (eds.) Cambridge Handbook of Psychology, Health and Medicine, 2nd, 675–8, Cambridge University Press.
- ↑ 67.0 67.1 Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004). Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18 (1): 37–48.
- ↑ 68.0 68.1 68.2 Stewart SA (2005). The effects of benzodiazepines on cognition. J Clin Psychiatry 66 (Suppl 2): 9–13.
- ↑ Hammersley D, Beeley L (1996). "The effects of medication on counselling" Palmer S, Dainow S, Milner P (eds.) Counselling: The BACP Counselling Reader, 211–4, Sage.
- ↑ Longo LP, Johnson B (2000). Addiction: part I. Benzodiazepines—side effects, abuse risk and alternatives. Am Fam Physician 61 (7): 2121–8.
- ↑ Nardi AE, Perna G (May 2006). Clonazepam in the treatment of psychiatric disorders: an update. Int Clin Psychopharmacol 21 (3): 131–42.
- ↑ Otto MW, Bruce SE, Deckersbach T (2005). Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. J Clin Psychiatry 66 (Suppl 2): 34–8.
- ↑ 73.0 73.1 73.2 Chouinard G (2004). Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65 (Suppl 5): 7–12.
- ↑ Harrison PC, Gelder MG, Cowen P (2006). "The misuse of alcohol and drugs" Shorter Oxford Textbook of Psychiatry, 5th, 461–2, Oxford University Press.
- ↑ Longmore M, Scally P, Collier J (2003). "Chapter 4" Oxford Handbook of Clinical Specialties, 6th, Oxford University Press.
- ↑ Ashton H (1991). Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 8 (1–2): 19–28.
- ↑ 77.0 77.1 77.2 77.3 Ashton CH (2002). Benzodiazepines: how they work & how to withdraw. The Ashton Manual. benzo.org.uk. URL accessed on 2009-05-27.
- ↑ Lal R, Gupta S, Rao R, Kattimani S (2007). "Emergency management of substance overdose and withdrawal" Substance Use Disorder (PDF), World Health Organisation. URL accessed 2009-06-06. "Generally, a longer-acting benzodiazepine such as chlordiazepoxide or diazepam is used and the initial dose titrated downward"
- ↑ (23 October 2007) "Alphabetical presentation of drugs" Desk Reference for Clinical Pharmacology, 2nd, USA: CRC Press.
- ↑ 80.0 80.1 80.2 80.3 (2006) Meyler L, Aronson JK Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions, 15th, 429–43, Elsevier.
- ↑ Committee on Safety of Medicines (1988). Benzodiazepines, dependence and withdrawal symptoms. (PDF) Medicines and Healthcare products Regulatory Agency. URL accessed on 2009-05-28.
- ↑ 82.0 82.1 82.2 82.3 Moody D (2004). "Drug interactions with benzodiazepines" Raymon LP, Mozayani A (eds.) Handbook of Drug Interactions: a Clinical and Forensic Guide, 3–88, Humana.
- ↑ Roach SS, Ford SM (2006). "Sedatives and hypnotics" Introductory Clinical Pharmacology, 8th, Lippincott Williams & Wilkins.
- ↑ Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (1998). Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 317 (7162): 839–43.
- ↑ American Academy of Pediatrics Committee on Drugs (1998). Neonatal drug withdrawal. Pediatrics 101 (6): 1079–88.
- ↑ Iqbal MM, Sobhan T, Ryals T (2002). Effects of commonly used benzodiazepines on the fetus, the neonate and the nursing infant. Psychiatr Serv 53 (1): 39–49.
- ↑ 87.0 87.1 Bogunovic OJ, Greenfield SF (2004). Practical geriatrics: Use of benzodiazepines among elderly patients. Psychiatr Serv 55 (3): 233–5.
- ↑ 88.0 88.1 Tariq SH, Pulisetty S (2008). Pharmacotherapy for insomnia. Clin Geriatr Med 24 (1): 93–105, vii.
- ↑ Bain KT (2006). Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 4 (2): 168–92.
- ↑ Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005). Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22 (9): 749–65.
- ↑ 91.0 91.1 (22 May 2009) Prescribing for Elderly Patients, 47-48, Wiley.
- ↑ (2006) Office care geriatrics, 260-262, Philadelphia: Lippincott Williams Wilkins.
- ↑ Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP (2005). Dementia associated with alcohol and other drug use. Int Psychogeriatr 17 (Suppl 1): S109–27.
- ↑ Verdoux H, Lagnaoui R, Begaud B (2005). Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 35 (3): 307–15.
- ↑ Snowden M, Sato K, Roy-Byrne P (2003). Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 51 (9): 1305–17.
- ↑ Wang PS, Brookhart MA, Setoguchi S, Patrick AR, Schneeweiss S (2006). Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep 6 (6): 490–5.
- ↑ Longo LP, Johnson B (April 2000). Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. Am Fam Physician 61 (7): 2121–8.
- ↑ 98.0 98.1 98.2 Olsen RW, Betz H (2006). "GABA and glycine" Siegel GJ, Albers RW, Brady S, Price DD (eds.) Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 7th, 291–302, Elsevier.
- ↑ 99.0 99.1 Zavala F (1997). Benzodiazepines, anxiety and immunity. Pharmacol Ther 75 (3): 199–216.
- ↑ 100.0 100.1 Narimatsu E, Niiya T, Kawamata M, Namiki A (2006). [The mechanisms of depression by benzodiazepines, barbiturates and propofol of excitatory synaptic transmissions mediated by adenosine neuromodulation]. Masui 55 (6): 684–91.
- ↑ 101.0 101.1 Madsen U, Bräuner-Osborne H, Greenwood JR, Johansen TN, Krogsgaard-Larsen P, Liljefors T, Nielsen M, Frølund B (2005). "GABA and Glutamate receptor ligands and their therapeutic potential in CNS disorders" Gad SC Drug Discovery Handbook, 797–907, Hoboken, N.J: Wiley-Interscience/J. Wiley.
- ↑ 102.0 102.1 Template:BlueBook1993; Moss GP (1998). Nomenclature of fused and bridged fused ring systems (IUPAC Recommendations 1998). Pure Appl Chem 70 (1): 143–216.
- ↑ CAS registry number:2898-08-0 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
- other names
- Ro 05-2921, dechlorodemethyldiazepam.
- ↑ Rudolph U, Möhler H (2006). GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 6 (1): 18–23.
- ↑ (28 August 1998) "Clinical psychopharmacology" Sciences Basic to Psychiatry, 2nd, 155–156, Churchill Livingstone. URL accessed 11-07-2009.
- ↑ Johnston GA (1996). GABAA receptor pharmacology. Pharmacol Ther 69 (3): 173–98.
- ↑ Wafford KA, Macaulay AJ, Fradley R, O'Meara GF, Reynolds DS, Rosahl TW (2004). Differentiating the role of gamma-aminobutyric acid type A (GABAA) receptor subtypes. Biochem Soc Trans 32 (Pt3): 553–6.
- ↑ Hevers W, Lüddens H (1998). The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 18 (1): 35–86.
- ↑ Arvat E, Giordano R, Grottoli S, Ghigo E (2002). Benzodiazepines and anterior pituitary function. J Endocrinol Invest 25 (8): 735–47.
- ↑ Zisterer DM, Williams DC (1997). Peripheral-type benzodiazepine receptors. Gen Pharmacol 29 (3): 305–14.
- ↑ 111.0 111.1 Norman TR, Ellen SR, Burrows GD (1997). Benzodiazepines in anxiety disorders: managing therapeutics and dependence. Med J Aust 167 (9): 490–5.
- ↑ Gaudreault P, Guay J, Thivierge RL, Verdy I (1991). Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. Drug Saf 6 (4): 247–65.
- ↑ Green RS, Godsoe SK, Sharma S, Palatnick W (2008). Toxicity, benzodiazepine. eMedicine. URL accessed on 2008-06-10.
- ↑ 114.0 114.1 Ramrakha P, Moore K (2004). "Chapter 14: Drug overdoses" Oxford Handbook of Acute Medicine, 2nd, Oxford University Press.
- ↑ Klein-Schwartz W, Oderda GM (1991). Poisoning in the elderly. Epidemiological, clinical and management considerations. Drugs Aging 1 (1): 67–89.
- ↑ Ramadan MI, Werder SF, Preskorn SH (2006). Protect against drug–drug interactions with anxiolytics. Curr Psychiatr 5 (5): 16–28.
- ↑ Seger DL (2004). Flumazenil—treatment or toxin. J Toxicol Clin Toxicol 42 (2): 209–16.
- ↑ Spivey WH (1992). Flumazenil and seizures: analysis of 43 cases. Clin Ther 14 (2): 292–305.
- ↑ Goldfrank LR (2002). Goldfrank's Toxicologic Emergencies, McGraw-Hill.
- ↑ International Narcotics Control Board (2003). List of psychotropic substances under international control. (PDF) URL accessed on 2008-12-17.
- ↑ List of drugs currently controlled under the misuse of drugs legislation. (PDF) UK Government Home Office. URL accessed on 2009-05-27.
- ↑ (20 December 2006) Drug Abuse Handbook, 2nd, United States of America: CRC Press.
- ↑ (11 April 2002) "Benzodiazepine abuse" Drink, Drugs and Dependence: From Science to Clinical Practice, 1st, 197–211, Routledge.
- ↑ Gerada C, Ashworth M (1997). ABC of mental health. Addiction and dependence—I: Illicit drugs. BMJ 315 (7103): 297–300.
- ↑ Loxley W (2007). Benzodiazepine use and harms among police detainees in Australia. Trends Issues Crime Crim Justice (336).
- ↑ Kintz P (2007). Bioanalytical procedures for detection of chemical agents in hair in the case of drug-facilitated crimes. Anal Bioanal Chem 388 (7): 1467–74.
- Ashton CH (2002). Benzodiazepines: how they work & how to withdraw. The Ashton Manual. benzo.org.uk. URL accessed on 2009-06-09.
- Ashton CH (2007). Benzodiazepine equivalence table. benzo.org.uk. URL accessed on 2009-06-09.
- Fruchtengarten L (1998). Benzodiazepines. PIM G008. International Programme on Chemical Safety (IPCS) INCHEM. URL accessed on 2009-06-09.
- Longo LP, Johnson B (2000). Addiction: part I. Benzodiazepines—side effects, abuse risk and alternatives. Am Fam Physician 61 (7): 2121–8.
- (2005). The complete story of the benzodiazepines. The Eaton T. Fores Research Center. URL accessed on 2009-06-09.
- Benzodiazepines advanced consumer information. Drugs.com. URL accessed on 2009-06-09.
Benzodiazepines (N05BA, N05CD)
Bromazepam • Camazepam • Carburazepam • Chlordiazepoxide • Cinolazepam • Clonazepam • Clorazepate • Cyprazepam • Delorazepam • Demoxepam • Diazepam • Doxefazepam • Elfazepam • Ethyl carfluzepate • Ethyl dirazepate • Ethyl loflazepate • Fletazepam • Fludiazepam • Flunitrazepam • Flurazepam • Flutemazepam • Flutoprazepam • Fosazepam • Gidazepam • Halazepam • Iclazepam • Lopirazepam • Lorazepam • Lormetazepam • Meclonazepam • Medazepam • Menitrazepam • Metaclazepam • Motrazepam • Nimetazepam • Nitrazepam • Nitrazepate • Nordazepam • Nortetrazepam • Oxazepam • Phenazepam • Pinazepam • Pivoxazepam • Prazepam • Proflazepam • Quazepam • QH-II-66 • Reclazepam • Sulazepam • Temazepam • Tetrazepam • Tolufazepam • Tuclazepam • Uldazepam
Psycholeptics: anxiolytics (N05B)
|Benzodiazepine||Diazepam - Chlordiazepoxide - Medazepam - Oxazepam - Potassium clorazepate - Lorazepam - Adinazolam - Bromazepam - Clobazam - Ketazolam - Prazepam - Alprazolam - Halazepam - Pinazepam - Camazepam - Nordazepam - Fludiazepam - Ethyl loflazepate - Etizolam - Clotiazepam - Cloxazolam - Tofisopam|
|Diphenylmethane||Hydroxyzine - Captodiame|
|Carbamates||Meprobamate - Emylcamate - Mebutamate|
|Azaspirodecanedione (serotonin receptor agonist)||Buspirone - Gepirone - Tandospirone|
|Other||Mephenoxalone - Gedocarnil - Etifoxine|
Psycholeptics: hypnotics and sedatives (N05C)
|Barbiturates||Pentobarbital - Amobarbital - Butobarbital - Barbital - Aprobarbital - Secobarbital - Talbutal - Vinylbital - Vinbarbital - Cyclobarbital - Heptabarbital - Reposal - Methohexital - Hexobarbital - Thiopental Ethallobarbital - Allobarbital - Proxibarbal - Phenobarbital|
|Aldehydes||Chloral hydrate - Chloralodol - Acetylglycinamide chloral hydrate - Dichloralphenazone - Paraldehyde|
|Benzodiazepine||Flurazepam - Nitrazepam - Temazepam - Flunitrazepam - Nimetazepam - Estazolam - Triazolam - Lormetazepam - Midazolam - Brotizolam - Quazepam - Loprazolam - Doxefazepam - Cinolazepam|
|Piperidinedione||Glutethimide - Methyprylon - Pyrithyldione|
|Nonbenzodiazepine||Zopiclone/Eszopiclone - Zolpidem - Zaleplon|
|Melatonin receptor||Melatonin - Ramelteon|
|Other||Methaqualone - Clomethiazole - Bromisoval - Carbromal - Scopolamine - Propiomazine - Triclofos - Ethchlorvynol - Valerian - Hexapropymate - Bromides - Apronal - Valnoctamide - Methylpentynol - Niaprazine - Dexmedetomidine|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|